Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025)
Candel Therapeutics (CADL) posted Income from Continuing Operations of 15227000.0 for Q4 2025, up 35.61% sequentially from 23649000.0 in Q3 2025, and down 79.58% YoY from 74586789.72 in Q4 2024.
Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Income from Continuing Operations for 6 years, with the latest figure at 15227000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 79.58% year-over-year to 15227000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 81447000.0 (down 14.32% YoY) and the FY2025 annual result came in at 109619000.0, down 83.05% from the prior year.
- Income from Continuing Operations rose to 15227000.0 in Q4 2025 per CADL's latest filing, from 23649000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4669000.0 in Q1 2021 and troughed at 38152000.0 in Q1 2022.
- A 5-year average of 15569800.0 and a median of 10179500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 717.13% in 2022, then soared 73.19% in 2023.
- Over 5 years, Income from Continuing Operations stood at 26084000.0 in 2021, then soared by 65.62% to 8967000.0 in 2022, then decreased by 12.96% to 10129000.0 in 2023, then climbed by 16.29% to 8479000.0 in 2024, then tumbled by 79.58% to 15227000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15227000.0, 23649000.0, and 21524000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.23 Mn |
| Sep 30, 2025 | -23.65 Mn |
| Jun 30, 2025 | -21.52 Mn |
| Mar 31, 2025 | -21.05 Mn |
| Dec 31, 2024 | -8.48 Mn |
| Sep 30, 2024 | -28.82 Mn |
| Jun 30, 2024 | -25.72 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Dec 31, 2023 | -10.13 Mn |
| Sep 30, 2023 | -9.52 Mn |
| Jun 30, 2023 | -19.57 Mn |
| Mar 31, 2023 | -10.23 Mn |
| Dec 31, 2022 | -8.97 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -38.15 Mn |
| Dec 31, 2021 | -26.08 Mn |
| Sep 30, 2021 | -7.90 Mn |
| Jun 30, 2021 | -5.32 Mn |
| Mar 31, 2021 | -4.67 Mn |